

Complete Listing of Claims

1. (Original) A method of treating memory disorders in individuals in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
2. (Original) The method of claim 1 wherein the nicotine antagonist is mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer.
3. (Original) The method of claim 2, wherein the effective amount of the nicotine antagonist is 0.005-1.00 mg/kg/day.
4. (Currently amended) The method of claim 1 in which the memory disorder is brought on by therapy using conventional neuroleptic drugs.
5. (Original) The method of claim 1 additionally comprising administration of an atypical neuroleptic drug.
6. (Original) A method of treating learning disorders in individuals in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
7. (Original) The method of claim 6, wherein the nicotine antagonist is mecamylamine, a mecamylamine analog, or a mecamylamine stereoisomer.
8. (Original) The method of claim 7, wherein the effective amount of the nicotine antagonist is 0.005-1.00 mg/kg/day.
9. (Original) A method of treating age-related cognitive disorders in an individual in need thereof, the method comprising administering to the individual an effective amount of a nicotine antagonist.
10. (Original) The method of claim 9, wherein the nicotine antagonist is mecamylamine, mecamylamine analog, or a mecamylamine stereoisomer.
11. (Original) The method of claim 9, wherein the effective amount of the nicotine antagonist is 0.005-1.00 mg/kg/day.
12. (Currently amended) The method of claim 9 in which the cognitive disorder is caused or exacerbated by therapy using conventional neuroleptic drugs.
13. (Original) The method of claim 9 additionally comprising administering an atypical neuroleptic drug.
14. (Original) A method of treating cognitive disorders in an individual in need thereof, the method comprising administering to the individual an effective amount of a partial nicotine agonist.

15. (New) The method of claim 2, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
16. (New) The method of claim 2, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
17. (New) The method of claim 2, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
18. (New) The method of claim 2, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
19. (New) The method of claim 2, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
20. (New) The method of claim 2, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
21. (New) The method of claim 2, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
22. (New) The method of claim 2, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.
23. (New) The method of claim 2, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.
24. (New) The method of claim 7, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
25. (New) The method of claim 7, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
26. (New) The method of claim 7, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
27. (New) The method of claim 7, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
28. (New) The method of claim 7, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
29. (New) The method of claim 7, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.

30. (New) The method of claim 7, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
31. (New) The method of claim 7, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.
32. (New) The method of claim 7, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.
33. (New) The method of claim 10, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
34. (New) The method of claim 10, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
35. (New) The method of claim 10, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
36. (New) The method of claim 10, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
37. (New) The method of claim 10, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
38. (New) The method of claim 10, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
39. (New) The method of claim 10, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
40. (New) The method of claim 10, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.
41. (New) The method of claim 10, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.
42. (New) A method for improving executive function in a patient suffering from executive dysfunction, the method comprising administering an effective amount of mecamlamine, a stereoisomer thereof, or an analog thereof.
43. (New) The method of claim 42, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
44. (New) The method of claim 42, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.

45. (New) The method of claim 42, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
46. (New) The method of claim 42, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
47. (New) The method of claim 42, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
48. (New) The method of claim 42, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
49. (New) The method of claim 42, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.
50. (New) The method of claim 42, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.
51. (New) The method of claim 42, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.
52. (New) A method for treating a patient suffering from attention deficit hyperactivity disorder, the method comprising administering an effective amount of mecamlamine, a stereoisomer thereof, or an analog thereof.
53. (New) The method of claim 52, wherein the effective amount is from about 0.001 mg/kg/day to about 10 mg/kg/day.
54. (New) The method of claim 52, wherein the effective amount is from about 0.002 mg/kg/day to about 7 mg/kg/day.
55. (New) The method of claim 52, wherein the effective amount is from about 0.005 mg/kg/day to about 2 mg/kg/day.
56. (New) The method of claim 52, wherein the effective amount is from about 0.005 mg/kg/day to about 10 mg/kg/day.
57. (New) The method of claim 52, wherein the effective amount is from about 0.01 mg/kg/day to about 1.5 mg/kg/day.
58. (New) The method of claim 52, wherein the effective amount is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
59. (New) The method of claim 52, wherein the effective amount is from about 0.03 mg/kg/day to about 0.1 mg/kg/day.

60. (New) The method of claim 52, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.

61. (New) The method of claim 52, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.

62. (New) A method for treating a patient suffering from bipolar disorder, the method comprising administering an effective amount of mecamlamine, a stereoisomer thereof, or an analog thereof.

63. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 10 mg/kg/day.

64. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 7 mg/kg/day.

65. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 2 mg/kg/day.

66. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 10 mg/kg/day.

67. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 1.5 mg/kg/day.

68. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 0.5 mg/kg/day.

69. (New) The method of claim 62, wherein the effective amount is from about 0.0 mg/kg/day to about 0.1 mg/kg/day.

70. (New) The method of claim 62, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered in a sustained or delayed release dosage form.

71. (New) The method of claim 62, wherein the mecamlamine, stereoisomer thereof, or analog thereof is administered by bronchial inhalation.